Safety and Efficacy of Adefovir Dipivoxil in Children and Adolescents With Chronic Hepatitis B
Completed · Phase 3 · Has a placebo group
Conditions studied: Chronic Hepatitis B
In brief
The purpose of this study is to investigate the efficacy and safety of adefovir dipivoxil for the treatment of chronic hepatitis B in children and adolescents (age 2 to less than 18 years) following 48 weeks of placebo-controlled, double-blind treatment and following an additional 192 weeks of open-label adefovir dipivoxil treatment.
Key facts
- Study ID
- NCT00095121
- Run by
- Gilead Sciences
- People needed
- 173
- Starts
- 2004-06-01
- Expected to finish
- 2010-04-01
- Last updated by the study team
- 2012-05-22
Who can join
Age: 2 and older, up to 17. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Study site — Boston, Massachusetts, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.